$NXTC has been discussed by 2 distinct FinTwit voices over the past 12 months, with 4 total mentions spanning from April 1, 2026 to July 14, 2026. Jacob Plieth (@jacobplieth) is the most active voice covering the stock with 4 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The biotech category dominates discussion of Nextcure Inc.

Discussion of $NXTC centered on clinical trial data and corporate developments. In early June 2026, Jacob Plieth highlighted concerns about the company's CDH6-targeting ADC SIM0505, a drug licensed from Simcere for $12 million, noting toxicity issues at the active dose and a 45% share decline. Later that same day, Plieth flagged specific efficacy data from the compound, commenting on PROC responses at an 8.0mg/kg dose deemed too toxic for phase 2 progression. By mid-July, Adam Feuerstein reported that Avere Therapeutics, featuring a former Akero executive team and a reverse merger into $NXTC with a $320 million private placement, had licensed an oral, weekly IL-23 drug from China's Hansoh.